Seth Lieblich is a Principal at 8VC, where he invests in and supports founders of life science companies. He has held previous roles in business development at Amgen and as a Chief Operating Officer at Protomer Technologies. He also has a PhD in Biochemistry and Molecular Biophysics from Caltech. Two publications authored by him include "Replacement of ProB28 by pipecolic acid protects insulin against fibrillation and slows hexamer dissociation" and "Incorporation of Non-Canonical Amino Acids into Proteins by Global Reassignment of Sense Codons".